Investing in the Future of Health & Innovation
Our Mission
"To deliver superior returns by investing in groundbreaking companies that are redefining the future of medicine and human health."
What Sets Us Apart
Our unique combination of scientific expertise and investment acumen positions us to identify and capitalize on the most promising opportunities in healthcare innovation.
Focused on Life Sciences & Healthcare
Deep specialization in biotech, pharma, medtech, and diagnostics sectors with unparalleled market insight.
Proprietary Due Diligence Models
Advanced analytical frameworks combining scientific validation with rigorous financial modeling.
Scientific and Financial Expertise
Our team combines PhD-level scientific knowledge with Wall Street investment experience.
Early Access to Disruptive Technologies
Strategic partnerships and networks provide privileged access to breakthrough innovations before they reach mainstream markets.
Our Leadership
Meet the experienced professionals driving innovation and excellence in healthcare investment.
William Soliman, Ph.D.
Founder, President & Chief Investment Officer
William Soliman brings over 20 years of leadership in the healthcare industry. With an uncommon depth of pharmaceutical, clinical, and regulatory expertise, he has built and scaled multiple enterprises in the healthcare industry, including founding the Accreditation Council for Medical Affairs (ACMA), the leading board-certification and accreditation organization with partnerships spanning over 1,000 pharmaceutical and biotechnology companies worldwide.
As a recognized national thought leader, he is a frequent commentator on pharmaceutical innovation and healthcare policy, appearing regularly on Fox News, ABC, NewsNation, and other major outlets. With an audience exceeding 400,000 followers across social media platforms, he is widely regarded for his ability to distill complex science into clear, actionable insights.
His professional experience extends from early-stage clinical trial design through regulatory approval and commercial launch. He has served in executive, board, and advisory capacities for global pharmaceutical leaders including AbbVie, Gilead Sciences, Merck, Boehringer Ingelheim, and Biovail. His direct involvement in clinical development programs, combined with deep regulatory and market-access insight, enables him to evaluate the healthcare landscape with a keen eye. Currently, he serves on the Forbes Technology Council and the McKinsey Health Technology Council. He previously held faculty appointments as Clinical Professor of Medicine at Seton Hall University and Touro College of Medicine & Pharmacy. His academic research career includes work at Columbia and NYU.
His education includes a Bachelor Degree (B.A.) from New York University (NYU), a Master Degree (M.Phil.), and Doctorate (Ph.D.) from Columbia University, with a focus on Biochemistry, Chemistry Education, and the Interface between Macroeconomics and Chemistry. He has over 30 scientific publications and was invited in March 2021 to give a congressional briefing to the U.S. Congress Health Subcommittee on professional standards in the pharmaceutical industry.
Eugene Prahin, MBA
Chief Operating Officer
Eugene Prahin serves as Chief Operating Officer with extensive leadership experience spanning investment management, fund operations, and biotechnology. Prior to joining the firm, he most recently served as Chief Operating Officer of Sparrow Capital, a multi-strategy investment manager with exposure to private equity, venture capital, real estate, and opportunistic strategies. In this role, he oversaw all fund and firm operations, managed portfolio company oversight, and guided multiple successful exits across diverse market environments.
In biotechnology, he has experience as Chief Financial Officer of Yamo Pharmaceuticals, an FDA Fast Track-designated company developing treatments targeting core symptoms of autism spectrum disorder. He joined at founding and led the company through multiple financing rounds, clinical advancement, and the successful execution of a Phase 2 trial. As co-founder and Chief Executive Officer of FEA Materials, he built the leading U.S. producer of scandium-enriched master alloys from technology development through corporate partnerships, initial commercial sales, and strategic engagement with the Department of Defense. His early career included roles with GSC Group and Lehman Brothers.
His education includes a Bachelor Degree (B.S.) Management with concentrations in Finance and International Business, from State University of New York (SUNY) Binghamton and a Masters in Business Administration (MBA) with a concentration in Finance from London Business School.
Emilio Escartin, M.S.
Head of Investor Relations
Emilio Escartin brings years of international experience in raising capital, private equity, venture capital, and investment banking across Europe, Latin America, the Middle East, and the United States. Previously, he was Chief Investment Officer of Güil Mobility Ventures, the corporate venture arm of Kaufmann Ventures, managing a global portfolio focused on disruptive mobility and technology investments. Also, he has held senior roles at 5-Capital, KD Funds (Generali Investments), EBN Capital, Diana Capital, and Bahrain Development Bank, collectively structuring, managing, and advising on funds exceeding $2 billion in assets. Early in his career, he worked in corporate finance and investment banking at HSBC and BDO, advising on IPOs, M&A transactions, and due diligence processes involving multi-billion dollars in enterprise value.
He holds a proven track record executing complex cross-border transactions and building long-term partnerships with sovereign wealth funds, institutional limited partners, funds of funds, family offices, and high-net-worth investors worldwide. He also serves as Visiting Professor of Finance and Capital Markets at IE Business School in Madrid, Spain.
His education includes a Bachelor Degree (B.B.A.) in Business Administration from Universidad Complutense de Madrid (CUNEF), a Master in Science (M.S.) from IESE Business School, and an Executive Certification in Microfinance and Microcredits from Harvard Kennedy School.
Michael Jeong, M.D.
Portfolio Manager
Michael Jeong serves as Portfolio Manager overseeing the long/short healthcare fund. In the past decade, he has worked primarily with healthcare investments in both equity and debt, including venture stage, private equity, long-only, and hedge funds.
Prior to joining the firm, he led successful thematic healthcare investment strategies at several multi-billion dollar equity investment funds, including Samsung Asset Management and Highland Capital Management. He has a proven track record of developing and implementing high-conviction thematic strategies and proprietary models focused on biotechnology, pharmaceuticals, and adjacent healthcare subsectors. His approach combines rigorous biomedical research, advanced data analysis, and deep clinical insight to identify transformative opportunities ahead of the market. His academic career includes genomics, neuropsychiatry, and medical oncology, including a faculty research position at Yale University School of Medicine.
His education includes a Bachelor Degree (B.S.) in Molecular, Developmental & Cell Biology from Yale University and Doctorate in Medicine (M.D.) with Honors in Epidemiology & Biostatistics from Tufts University School of Medicine.